The Medical Letter on Drugs and Therapeutics
Bromocriptine (Cycloset) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new tablet formulation of bromocriptine mesylate (Cycloset – VeroScience) for treatment of type 2 diabetes in adults. Bromocriptine (Parlodel, and others) is an ergot-derived dopamine agonist that has been used for more than 20 years to treat hyperprolactinemia, acromegaly, Parkinson’s disease and restless leg syndrome.

MECHANISM OF ACTION — The mechanism of action of bromocriptine in treating diabetes is unknown. It is thought to involve increased dopaminergic activity in the hypothalamus.1 Bromocriptine decreases postprandial serum glucose concentrations without increasing serum insulin concentrations. In some animal studies, bromocriptine given early in the day prevented the development of insulin resistance and decreased endogenous glucose production.

PHARMACOKINETICS — The new tablet formulation of bromocriptine is 65-95% ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bromocriptine (Cycloset) for Type 2 Diabetes
Article code: 1353a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian